OncoMatch/Clinical Trials/NCT06492460
2 Courses of Concurrent Cisplatin Chemoradiotherapy After Surgery for High-risk Head and Neck Squamous Cell Carcinoma
Is NCT06492460 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies Drug：Cisplatin for squamous cell carcinoma of head and neck.
Treatment: Drug：Cisplatin — The main objective of this trial was to determine the value of 2 courses of cisplatin concurrent chemotherapy in postoperative adjuvant radiotherapy for high-risk head and neck squamous cell carcinoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Required: Stage III, IV
Prior therapy
Must have received: surgery — radical
Radical surgery has been performed with high risk factors (one of below)
Cannot have received: chemotherapy
Exception: induction chemotherapy prior to surgery
Previous chemotherapy (except induction chemotherapy prior to surgery)
Cannot have received: radiation therapy
Previous radiation therapy
Lab requirements
Blood counts
WBC > 4×10^9/L; hemoglobin > 120g/L in males, 110g/L in females; platelet count > 100×10^9/L
Kidney function
creatinine clearance > 60 ml/min
Liver function
ALT, AST < 1.5x ULN; ALP < 2.5x ULN; bilirubin < ULN
Normal bone marrow function: white blood cell count > 4×10^9/L, hemoglobin > 120g/L in males, 110g/L in females, platelet count > 100×10^9/L. Normal liver function: ALT, AST < 1.5x ULN; ALP < 2.5x ULN; bilirubin < ULN. Normal renal function: creatinine clearance > 60 ml/min.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify